Lacutamab

DRUG4 trials

Sponsors

Innate Pharma, LYSARC, The Lymphoma Academic Research Organisation

Conditions

Advanced T-Cell Lymphomas (TCL)IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERAL T-CELL LYMPHOMAPeripheral T Cell LymphomaRelapse/Recurrencei.e. Cutaneous T Cell Lymphomas (CTCL) CTCL subtypes under investigation: relapsed/refractory Sézary Syndrome (SS)stage IB to IV Mycosis Fungoides (MF).

Phase 1

Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2

CompletedNCT05321147

Innate PharmaPeripheral T Cell Lymphoma

Start: 2022-03-17End: 2024-02-08Updated: 2024-03-28

Phase 2

Study of Lacutamab in Peripheral T-cell Lymphoma

Active, not recruitingNCT04984837

The Lymphoma Academic Research OrganisationPeripheral T Cell Lymphoma, Relapse/Recurrence

Start: 2021-10-05End: 2028-04-30Updated: 2026-06-04

TELLOMAK: T-cell Lymphoma anti-KIR3DL2 therapy. An open label, multi-cohort, multi-center phase II study evaluating the efficacy and safety of IPH4102 alone or in combination with chemotherapy in patients with advanced T-cell lymphoma.

CompletedCTIS2023-507777-18-00

Innate PharmaAdvanced T-Cell Lymphomas (TCL), i.e. Cutaneous T Cell Lymphomas (CTCL) CTCL subtypes under investigation: relapsed/refractory Sézary Syndrome (SS), stage IB to IV Mycosis Fungoides (MF).

Start: 2019-03-19End: 2025-12-23Target: 104Updated: 2025-08-04

KILT - A RANDOMIZED NON COMPARATIVE PHASE II STUDY OF LACUTAMAB WITH GEMOX VERSUS GEMOX ALONE IN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA

RecruitingCTIS2024-513252-15-00

LYSARCIN RELAPSED/REFRACTORY PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA

Start: 2021-01-28Target: 56Updated: 2025-10-10

Related Papers

Lacutamab in patients with relapsed and refractory Sézary syndrome: Long term follow-up from the TELLOMAK phase 2 trial.

Journal of Clinical Oncology2025-05-282 citations

Lacutamab in patients with relapsed and/or refractory mycosis fungoides: Long-term follow-up and translational data from the TELLOMAK phase 2 trial.

Journal of Clinical Oncology2025-05-28

Strategies to Develop Anti-KIR Mab Lacutamab in Patients with Peripheral T-Cell Lymphoma: Preliminary Monotherapy Clinical Data and Pre-Clinical Combinability Data

Blood2023-11-023 citations

KILT: A RANDOMIZED NON‐COMPARATIVE PHASE II LYSA STUDY OF LACUTAMAB WITH GEMOX VERSUS GEMOX IN RELAPSED/REFRACTORY PERIPHERAL T‐CELL LYMPHOMA

Hematological Oncology2023-06-011 citations

KIR3DL2 contributes to the typing of acute adult T-cell leukemia and is a potential therapeutic target

Blood2022-06-109 citations